A novel live vector group a streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group a streptococci

Aniela Wozniak, Patricia Garciá, Enrique A. Geoffroy, Daniel B. Aguirre, Samantha A. González, Victoria A. Sarno, James Dale, Francisco J. Salazar-Echegarai, Andrea Vera, Susan M. Bueno, Alexis M. Kalergis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The availability of a protective vaccine against Streptococcus pyogenes (group A Streptococcus [GAS]) is a priority for public health worldwide. Here, we have generated six live vaccine strains, each engineered to express an N-terminal M protein peptide from one of six of the most prevalent emm types of GAS (M1, M2, M4, M9, M12, and M28). The vaccine strains are based on a food-grade Lactococcus lactis strain and do not bear any antibiotic resistance. Mice immunized with the vaccine strain expressing the M9 peptide (termed here the L. lactis M9 strain) showed high titers of serum antibodies when delivered intranasally. Mice immunized with the L. lactis M9 strain were protected against infection after intranasal challenge with type 9 streptococci. Several parameters of disease, such as weight loss, body temperature, colony counts in mouth washes, and lung histology, were significantly improved in immunized mice compared to naive control mice. Our results indicate that intranasal delivery of the L. lactis M9 strain live bacterial vaccine induced GAS-specific IgG titers, prevented pharyngeal colonization of GAS, and protected mice from disease upon challenge. The design of this vaccine prototype may provide a lower cost alternative to vaccines comprised of purified recombinant proteins.

Original languageEnglish (US)
Pages (from-to)1343-1349
Number of pages7
JournalClinical and Vaccine Immunology
Volume21
Issue number9
DOIs
StatePublished - Jan 1 2014

Fingerprint

Streptococcus
Vaccines
Lactococcus lactis
Infection
Bacterial Vaccines
Histology
Streptococcus pyogenes
Public health
Microbial Drug Resistance
Body Temperature
Recombinant Proteins
Mouth
Weight Loss
Public Health
Immunoglobulin G
Availability
Anti-Bacterial Agents
Costs and Cost Analysis
Food
Lung

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

A novel live vector group a streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group a streptococci. / Wozniak, Aniela; Garciá, Patricia; Geoffroy, Enrique A.; Aguirre, Daniel B.; González, Samantha A.; Sarno, Victoria A.; Dale, James; Salazar-Echegarai, Francisco J.; Vera, Andrea; Bueno, Susan M.; Kalergis, Alexis M.

In: Clinical and Vaccine Immunology, Vol. 21, No. 9, 01.01.2014, p. 1343-1349.

Research output: Contribution to journalArticle

Wozniak, A, Garciá, P, Geoffroy, EA, Aguirre, DB, González, SA, Sarno, VA, Dale, J, Salazar-Echegarai, FJ, Vera, A, Bueno, SM & Kalergis, AM 2014, 'A novel live vector group a streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group a streptococci', Clinical and Vaccine Immunology, vol. 21, no. 9, pp. 1343-1349. https://doi.org/10.1128/CVI.00330-14
Wozniak, Aniela ; Garciá, Patricia ; Geoffroy, Enrique A. ; Aguirre, Daniel B. ; González, Samantha A. ; Sarno, Victoria A. ; Dale, James ; Salazar-Echegarai, Francisco J. ; Vera, Andrea ; Bueno, Susan M. ; Kalergis, Alexis M. / A novel live vector group a streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group a streptococci. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 9. pp. 1343-1349.
@article{7423585bb84f48b28aebff001c3c870d,
title = "A novel live vector group a streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group a streptococci",
abstract = "The availability of a protective vaccine against Streptococcus pyogenes (group A Streptococcus [GAS]) is a priority for public health worldwide. Here, we have generated six live vaccine strains, each engineered to express an N-terminal M protein peptide from one of six of the most prevalent emm types of GAS (M1, M2, M4, M9, M12, and M28). The vaccine strains are based on a food-grade Lactococcus lactis strain and do not bear any antibiotic resistance. Mice immunized with the vaccine strain expressing the M9 peptide (termed here the L. lactis M9 strain) showed high titers of serum antibodies when delivered intranasally. Mice immunized with the L. lactis M9 strain were protected against infection after intranasal challenge with type 9 streptococci. Several parameters of disease, such as weight loss, body temperature, colony counts in mouth washes, and lung histology, were significantly improved in immunized mice compared to naive control mice. Our results indicate that intranasal delivery of the L. lactis M9 strain live bacterial vaccine induced GAS-specific IgG titers, prevented pharyngeal colonization of GAS, and protected mice from disease upon challenge. The design of this vaccine prototype may provide a lower cost alternative to vaccines comprised of purified recombinant proteins.",
author = "Aniela Wozniak and Patricia Garci{\'a} and Geoffroy, {Enrique A.} and Aguirre, {Daniel B.} and Gonz{\'a}lez, {Samantha A.} and Sarno, {Victoria A.} and James Dale and Salazar-Echegarai, {Francisco J.} and Andrea Vera and Bueno, {Susan M.} and Kalergis, {Alexis M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/CVI.00330-14",
language = "English (US)",
volume = "21",
pages = "1343--1349",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - A novel live vector group a streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group a streptococci

AU - Wozniak, Aniela

AU - Garciá, Patricia

AU - Geoffroy, Enrique A.

AU - Aguirre, Daniel B.

AU - González, Samantha A.

AU - Sarno, Victoria A.

AU - Dale, James

AU - Salazar-Echegarai, Francisco J.

AU - Vera, Andrea

AU - Bueno, Susan M.

AU - Kalergis, Alexis M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The availability of a protective vaccine against Streptococcus pyogenes (group A Streptococcus [GAS]) is a priority for public health worldwide. Here, we have generated six live vaccine strains, each engineered to express an N-terminal M protein peptide from one of six of the most prevalent emm types of GAS (M1, M2, M4, M9, M12, and M28). The vaccine strains are based on a food-grade Lactococcus lactis strain and do not bear any antibiotic resistance. Mice immunized with the vaccine strain expressing the M9 peptide (termed here the L. lactis M9 strain) showed high titers of serum antibodies when delivered intranasally. Mice immunized with the L. lactis M9 strain were protected against infection after intranasal challenge with type 9 streptococci. Several parameters of disease, such as weight loss, body temperature, colony counts in mouth washes, and lung histology, were significantly improved in immunized mice compared to naive control mice. Our results indicate that intranasal delivery of the L. lactis M9 strain live bacterial vaccine induced GAS-specific IgG titers, prevented pharyngeal colonization of GAS, and protected mice from disease upon challenge. The design of this vaccine prototype may provide a lower cost alternative to vaccines comprised of purified recombinant proteins.

AB - The availability of a protective vaccine against Streptococcus pyogenes (group A Streptococcus [GAS]) is a priority for public health worldwide. Here, we have generated six live vaccine strains, each engineered to express an N-terminal M protein peptide from one of six of the most prevalent emm types of GAS (M1, M2, M4, M9, M12, and M28). The vaccine strains are based on a food-grade Lactococcus lactis strain and do not bear any antibiotic resistance. Mice immunized with the vaccine strain expressing the M9 peptide (termed here the L. lactis M9 strain) showed high titers of serum antibodies when delivered intranasally. Mice immunized with the L. lactis M9 strain were protected against infection after intranasal challenge with type 9 streptococci. Several parameters of disease, such as weight loss, body temperature, colony counts in mouth washes, and lung histology, were significantly improved in immunized mice compared to naive control mice. Our results indicate that intranasal delivery of the L. lactis M9 strain live bacterial vaccine induced GAS-specific IgG titers, prevented pharyngeal colonization of GAS, and protected mice from disease upon challenge. The design of this vaccine prototype may provide a lower cost alternative to vaccines comprised of purified recombinant proteins.

UR - http://www.scopus.com/inward/record.url?scp=84940354904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940354904&partnerID=8YFLogxK

U2 - 10.1128/CVI.00330-14

DO - 10.1128/CVI.00330-14

M3 - Article

C2 - 25056362

AN - SCOPUS:84940354904

VL - 21

SP - 1343

EP - 1349

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 9

ER -